Fresenius 

M$0
767
+M$0+0% Saturday 05:07

统计数据

当日最高
-
当日最低
-
52周最高
-
52周最低
-
成交量
-
平均成交量
-
市值
-
市盈率
-
股息收益率
-
股息
-

即将到来

股息

0%股息收益率
10年增长
N/A
5年增长
N/A
3年增长
N/A
1年增长
N/A

收益

6Nov预期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一个
-1.18
-0.5
0.18
0.87
预期每股收益
0.73740253572
实际每股收益
N/A

人们还关注

此列表基于关注FRE.MX的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。

关于

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Show more...
首席执行官
Mr. Michael Sen
员工
175771
国家
US
ISIN
DE0005785604

上市公司